Veritas leads Puerto Rico partnership with approval of new Investigation License

SAN JUAN, Puerto Rico, Feb. 11, 2019 (GLOBE NEWSWIRE) — Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), in partnership with the Institute for Medical Cannabis (“IMC”) and the Fundación de Investigación (“FDI”) were approved this past Friday for an Investigation License from the Commonwealth of Puerto Rico Medicinal Cannabis Regulatory Board allowing clinical evaluation of their lead cannabis product (“CTL-X”) in alleviating acute pain. IMC and FDI represent two of Puerto Rico’s leading researchers in medicinal cannabis. The concession is also the first of its kind, representing the first collaboration of such by local partners and a foreign-owned and publicly-traded entity.

The trio’s license marks the commencement of the first human trials for medicinal cannabis to be carried out on the island since the approval of the Medicinal Cannabis Act of 2017

... read more at: https://globenewswire.com/news-release/2019/02/11/1716845/0/en/Veritas-leads-Puerto-Rico-partnership-with-approval-of-new-Investigation-License.html

by